{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:54:39Z","timestamp":1793141679179,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"],"award-info":[{"award-number":["H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109121 and 24ek0109633h0002"],"award-info":[{"award-number":["JP17ek0109121 and 24ek0109633h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["23K09729"],"award-info":[{"award-number":["23K09729"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the ability to discriminate giant cell arteritis (GCA) from Takayasu arteritis (TAK) according to the modified 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology (ACR\/EULAR) GCA classification criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients enrolled in the Japanese nationwide retrospective registry were evaluated using the criteria with partial modification; wall thickening of descending thoracic-abdominal aorta were mainly diagnosed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging instead of evaluating with positron emission tomography (PET)-CT. The discriminability of the criteria was evaluated using C-statistic (&gt;\u20090.7: good ability).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Newly diagnosed patients with GCA (<jats:italic>n<\/jats:italic>\u2009=\u2009139) and TAK (<jats:italic>n<\/jats:italic>\u2009=\u2009129) were assessed, and 23.3% of TAK were aged 50\u00a0years or older at onset. The sensitivity of the modified 2022 ACR\/EULAR GCA classification criteria with a score\u2009\u2265\u20096 was 82.0%, 68.5%, and 32.1% in all GCA, GCA with large-vessel involvement, and GCA without cranial arteritis, respectively. The specificity of the modified criteria was 96.1% for the 129 TAK as controls. Five patients with late-onset TAK met the modified criteria, and four had cranial signs and symptoms, two had bilateral axillary artery involvement, and four had descending thoracic-abdominal aorta involvement. The discriminability of the criteria was good (C-statistic: 0.986, 95% confidence interval [CI]: 0.976\u20130.996) and remained good after excluding age (C-statistic: 0.927, 95% CI: 0.894\u20130.961). The discriminability of a set of large-vessel lesions (bilateral axillary artery and descending thoracic-abdominal aorta) and inflammatory markers was markedly decreased with poor C-statistic value (C-statistic: 0.598, 95% CI: 0.530\u20130.667). Discriminability was improved after adding polymyalgia rheumatica (PMR) (C-statistic: 0.757, 95% CI: 0.700\u20130.813) or age (C-statistic: 0.913, 95%CI: 0.874\u20130.951) to the set of large-vessel lesions. In GCA patients with a score\u2009\u2264\u20095, 52% had bilateral subclavian and\/or axillary artery involvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The modified 2022 ACR\/EULAR GCA classification criteria well performed in classifying GCA and TAK without PET-CT in routine clinical practice. A set of items included in the modified GCA classification criteria had good discriminative ability for GCA and TAK, even when age was excluded. However, age restriction or PMR was required to distinguish GCA without cranial lesions from TAK.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13075-025-03486-y","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T09:50:41Z","timestamp":1738317041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Performance of the modified 2022 ACR\/EULAR giant cell arteritis classification criteria without age restriction for discriminating from Takayasu arteritis"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7494","authenticated-orcid":false,"given":"Takahiko","family":"Sugihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito A.","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Maejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Komagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taio","family":"Naniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Nagafuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tanemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohko","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Amiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Muso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Komatsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"1","key":"3486_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3486_CR2","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021;73(8):1349\u201365.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3486_CR3","doi-asserted-by":"publisher","first-page":"e001003","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti S, Agueda AF, Luqmani RA, Buttgereit F, Cid M, Dejaco C, et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open. 2019;5(2):e001003.","journal-title":"RMD Open"},{"issue":"8","key":"3486_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3486_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.41165","volume":"72","author":"KB Gribbons","year":"2020","unstructured":"Gribbons KB, Ponte C, Craven A, Robson JC, Suppiah R, Luqmani R, et al. Diagnostic assessment strategies and disease subsets in giant cell arteritis: data from an international observational cohort. Arthritis Rheumatol. 2020;72(4):667\u201376.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"3486_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1136\/annrheumdis-2011-200795","volume":"71","author":"PC Grayson","year":"2012","unstructured":"Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, et al. Distribution of arterial lesions in Takayasu\u2019s arteritis and giant cell arteritis. Ann Rheum Dis. 2012;71(8):1329\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3486_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MD.0b013e3181af70c1","volume":"88","author":"K Maksimowicz-McKinnon","year":"2009","unstructured":"Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore). 2009;88(4):221\u20136.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"3486_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/annrheumdis-2019-216145","volume":"79","author":"D Michailidou","year":"2020","unstructured":"Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC. Clinical symptoms and associated vascular imaging findings in Takayasu\u2019s arteritis compared to giant cell arteritis. Ann Rheum Dis. 2020;79(2):262\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3486_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/acr.24055","volume":"72","author":"KB Gribbons","year":"2020","unstructured":"Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns of arterial disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care Res (Hoboken). 2020;72(11):1615\u201324.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"3486_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/art.42325","volume":"74","author":"C Ponte","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology\/EULAR Classification Criteria for Giant Cell Arteritis. Arthritis Rheumatol. 2022;74(12):1881\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3486_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13075-020-02171-6","volume":"22","author":"T Sugihara","year":"2020","unstructured":"Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, et al. Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Res Ther. 2020;22(1):72.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3486_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/mr\/roac122","volume":"33","author":"T Sugihara","year":"2023","unstructured":"Sugihara T, Uchida HA, Yoshifuji H, Maejima Y, Naniwa T, Katsumata Y, et al. Association between the patterns of large-vessel lesions and treatment outcomes in patients with large-vessel giant cell arteritis. Mod Rheumatol. 2023;33(6):1145\u201353.","journal-title":"Mod Rheumatol"},{"key":"3486_CR13","doi-asserted-by":"crossref","unstructured":"Uchida HA, Nakaoka Y, Sugihara T, Yoshifuji H, Maejima Y, Watanabe Y, et al. Clinical characteristics and treatment outcomes of patients with newly diagnosed Takayasu arteritis in japan during the first 2 years of treatment- a nationwide retrospective cohort study. Circ J. 2024. online ahead of print.","DOI":"10.1253\/circj.CJ-24-0178"},{"issue":"18","key":"3486_CR14","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.114.012547","volume":"132","author":"Y Watanabe","year":"2015","unstructured":"Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu Arteritis observed from cross-country research in Japan: age and sex specificity. Circulation. 2015;132(18):1701\u20139.","journal-title":"Circulation"},{"issue":"3","key":"3486_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1253\/circj.CJ-23-0656","volume":"88","author":"H Yoshifuji","year":"2024","unstructured":"Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, et al. Organ damage and quality of life in Takayasu Arteritis - evidence from a national registry analysis. Circ J. 2024;88(3):285\u201394.","journal-title":"Circ J"},{"issue":"2","key":"3486_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","volume":"84","author":"M Isobe","year":"2020","unstructured":"Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al. JCS 2017 guideline on management of vasculitis syndrome- digest version. Circ J. 2020;84(2):299\u2013359.","journal-title":"Circ J"},{"issue":"12","key":"3486_CR17","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/ard-2022-223482","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022;81(12):1654\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3486_CR18","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/rheumatology\/keu395","volume":"54","author":"T Sugihara","year":"2015","unstructured":"Sugihara T, Ishizaki T, Hosoya T, Iga S, Yokoyama W, Hirano F, et al. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). Rheumatology (Oxford). 2015;54(5):798\u2013807.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"3486_CR19","doi-asserted-by":"publisher","first-page":"103413","DOI":"10.1016\/j.autrev.2023.103413","volume":"22","author":"J Narvaez","year":"2023","unstructured":"Narvaez J, Estrada P, Vidal-Montal P, Nolla JM. Performance of the new 2022 ACR\/EULAR classification criteria for giant cell arteritis in clinical practice in relation to its clinical phenotypes. Autoimmun Rev. 2023;22(10):103413.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3486_CR20","doi-asserted-by":"publisher","first-page":"e002970","DOI":"10.1136\/rmdopen-2022-002970","volume":"9","author":"J Molina-Collada","year":"2023","unstructured":"Molina-Collada J, Castrejon I, Monjo I, Fernandez-Fernandez E, Torres Ortiz G, Alvaro-Gracia JM, et al. Performance of the 2022 ACR\/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care. RMD Open. 2023;9(2):e002970.","journal-title":"RMD Open"},{"issue":"3","key":"3486_CR21","doi-asserted-by":"publisher","first-page":"e003080","DOI":"10.1136\/rmdopen-2023-003080","volume":"9","author":"M van Nieuwland","year":"2023","unstructured":"van Nieuwland M, van Bon L, Vermeer M, Brouwer E, Alves C. External validation of the 2022 ACR\/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic. RMD Open. 2023;9(3):e003080.","journal-title":"RMD Open"},{"issue":"6","key":"3486_CR22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/art.42440","volume":"75","author":"AK Hemmig","year":"2023","unstructured":"Hemmig AK, Aschwanden M, Imfeld S, Berger CT, Daikeler T. A diagnostic performance study of the 2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis in a cohort of patients presenting with suspected giant cell arteritis. Arthritis Rheumatol. 2023;75(6):1075\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"3486_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"3486_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3899\/jrheum.181219","volume":"47","author":"T Mutoh","year":"2020","unstructured":"Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu Arteritis. J Rheumatol. 2020;47(2):255\u201363.","journal-title":"J Rheumatol"},{"issue":"2","key":"3486_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acr.22931","volume":"69","author":"B Gudbrandsson","year":"2017","unstructured":"Gudbrandsson B, Molberg O, Garen T, Palm O. Prevalence, incidence, and disease characteristics of Takayasu arteritis by ethnic background: data from a large, population-based cohort resident in Southern Norway. Arthritis Care Res (Hoboken). 2017;69(2):278\u201385.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3486_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/mr\/road019","volume":"34","author":"N Konda","year":"2023","unstructured":"Konda N, Sakai R, Saeki K, Matsubara Y, Nakamura Y, Miyamae T, et al. Nationwide clinical and epidemiological study of large-vessel vasculitis in Japan in 2017. Mod Rheumatol. 2023;34(1):167\u201374.","journal-title":"Mod Rheumatol"},{"issue":"13","key":"3486_CR27","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1007\/s00259-017-3774-5","volume":"44","author":"H de Boysson","year":"2017","unstructured":"de Boysson H, Dumont A, Liozon E, Lambert M, Boutemy J, Maigne G, et al. Giant-cell arteritis: concordance study between aortic CT angiography and FDG-PET\/CT in detection of large-vessel involvement. Eur J Nucl Med Mol Imaging. 2017;44(13):2274\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"3486_CR28","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/annrheumdis-2018-213102","volume":"77","author":"KA Quinn","year":"2018","unstructured":"Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, et al. Comparison of magnetic resonance angiography and (18)F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018;77(8):1165\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3486_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/ard-2023-224543","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco C, Ramiro S, Bond M, Bosch P, Ponte C, Mackie SL, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83(6):741\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3486_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","volume":"42","author":"A Brack","year":"1999","unstructured":"Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311\u20137.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3486_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54(3):463\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3486_CR32","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2665-9913(24)00027-4","volume":"6","author":"A Sebastian","year":"2024","unstructured":"Sebastian A, van der Geest KSM, Tomelleri A, Macchioni P, Klinowski G, Salvarani C, et al. Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study. Lancet Rheumatol. 2024;6(5):e291\u20139.","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"3486_CR33","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1136\/annrheumdis-2020-218631","volume":"81","author":"J Molina Collada","year":"2022","unstructured":"Molina Collada J, Martinez-Barrio J, Serrano-Benavente B, Castrejon I, Caballero Motta LR, TrivesFolguera L, et al. Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care. Ann Rheum Dis. 2022;81(9):e175.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3486_CR34","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1093\/rheumatology\/keaa102","volume":"59","author":"H Hop","year":"2020","unstructured":"Hop H, Mulder DJ, Sandovici M, Glaudemans A, van Roon AM, Slart R, et al. Diagnostic value of axillary artery ultrasound in patients with suspected giant cell arteritis. Rheumatology (Oxford). 2020;59(12):3676\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3486_CR35","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/rheumatology\/keac478","volume":"62","author":"AC Bull Haaversen","year":"2023","unstructured":"Bull Haaversen AC, Brekke LK, Kermani TA, Molberg O, Diamantopoulos AP. Extended ultrasound examination identifies more large vessel involvement in patients with giant cell arteritis. Rheumatology (Oxford). 2023;62(5):1887\u201394.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03486-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03486-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03486-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T09:50:48Z","timestamp":1738317048000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03486-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3486"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03486-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research in Japan. The institutional review board of Tokyo Medical and Dental University as the main center (approval number: M2000-2084-01) and the additional 23 institutions approved our retrospective study without personally identifiable information. Patients received posters informing the present study, or the posters were displayed in the outpatient clinic of each facility.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TS has received research grants from AsahiKASEI Co., Ltd., Daiichi Sankyo., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical. TS has received speaker\u2019s fee from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., and Taisho Pharmaceutical Co., Ltd.. MH has received research grants from Boehringer-Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Teijin Pharma Ltd. MH has received speaker\u2019s fee from Boehringer-Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Teijin Pharma Ltd. MH is a consultant for Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma. HAU belongs to the Department of Chronic Kidney Disease and Cardiovascular Disease which is endowed by Olba Healthcare Holdings, Boehringer Ingelheim, and Terumo Corporation. HY has received lecture fees from Chugai Pharmaceutical and consulting fees from Janssen. HD has received speaking fees, and\/or honoraria from Abbvie, Asahi Kasei Pharma, Astellas, UCB Pharmaceutical, Ayumi Pharmaceutical, GlaxoSmithKline, Novartis Pharma, Eli Lilly Japan, and AstraZeneca. YK has received speaker\u2019s fee from GlaxoSmithKline. NT has received research grants from Asahi Kasei Pharma, Asahi Kasei Medical, Ayumi, AbbVie, Eisai, Nippon Boehringer Ingelheim, Taisho, Tanabe Mitsubishi, Chugai. NT has received speaker\u2019s fee and\/or consulting fee from Asahi Kasei Pharma, AstraZeneca, AbbVie, Eli Lilly Japan, GlaxoSmithKline, Chugai, Novartis, Bristol Myers Squibb, Janssen. YN has received consulting fees from AbbVie, Janssen Pharmaceutical KK, and Chugai, and has received lecture fees from AbbVie and Chugai. YM, JI and YW has nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}